Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy

Colleen K. Spees; Kelly J. Kelleher; Ronney Abaza; Steven K. Clinton

doi:10.1016/j.eucr.2015.01.002

Urology Case Reports (Mar 2015)

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy

Colleen K. Spees,
Kelly J. Kelleher,
Ronney Abaza,
Steven K. Clinton

Affiliations

Colleen K. Spees: Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, USA
Kelly J. Kelleher: College of Public Health, The Ohio State University, Columbus, OH, USA
Ronney Abaza: Department of Urology, The Ohio State University College of Medicine, Columbus, OH, USA
Steven K. Clinton: Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

DOI: https://doi.org/10.1016/j.eucr.2015.01.002
Journal volume & issue: Vol. 3, no. 2
pp. 21 – 23

Abstract

Read online

Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemotherapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors institution of screening at earlier ages.

Published in Urology Case Reports

ISSN: 2214-4420 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the genitourinary system. Urology
Website: http://www.urologycasereports.com/

About the journal

Abstract

Keywords